Redeye retains its positive view of Hansa Biopharma following a transformative second quarter. The company closed its EUR115m out-licensing of Idefirix in Europe to SERB Pharmaceuticals on July 1, banking a EUR110m upfront payment that funds the pending US launch without diluting shareholders. With pro forma cash of roughly SEK1.8bn supporting operations well into 2028, we see the FDA's December 19, 2026 PDUFA date as the single most important catalyst ahead. We reiterate our base case of SEK85.
LÄS MER
